Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain

Gene Therapy

Volumn 20, Issue 12, 2013, Pages 1178-1183

  San Sebastian, W ^a   Samaranch, L ^a   Heller, G ^a   Kells, A P ^a   Bringas, J ^a   Pivirotto, P ^a   Forsayeth, J ^a   Bankiewicz, K S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AAV6; axonal transport; convection enhanced delivery; Huntington's disease; MRI guided

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 6; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CAUDATE NUCLEUS; FRONTAL CORTEX; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MACACA FASCICULARIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NERVE CELL; NERVE FIBER TRANSPORT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RETROGRADE NERVE FIBER TRANSPORT; SUBSTANTIA NIGRA PARS COMPACTA; THALAMUS; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 6; MACACA; PRIMATES; RATTUS;

ANIMALS; ASTROCYTES; AXONAL TRANSPORT; AXONS; BRAIN; CAUDATE NUCLEUS; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; MACACA FASCICULARIS; MAGNETIC RESONANCE IMAGING; NEURONS; PUTAMEN; RATS; TRANSDUCTION, GENETIC; VIRAL TROPISM;

EID: 84890124857     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.48     Document Type: Article

References (24)

1. Hennig AK, Levy B, Ogilvie JM, Vogler CA, Galvin N, Bassnett S et al. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci 2003; 23: 3302-3307.
2. Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 2011; 19: 922-927.
3. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 2009; 106: 2407-2411.
4. Hadaczek P, Kohutnicka M, Krauze MT, Bringas J, Pivirotto P, Cunningham J et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 2006; 17: 291-302.
5. Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Therapy 2013; 20: 348-352.
6. Hadaczek P, Forsayeth J, Mirek H, Munson K, Bringas J, Pivirotto P et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: Vector trafficking and immune response. Hum Gene Ther 2009; 20: 225-237.
7. Bobo R, Laske D, Akbasak A, Morrison P, Dedrick R, Oldfield E. Convectionenhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080.
8. Hadaczek P, Kohutnicka M, Krauze MT, Bringas J, Pivirotto P, Cunningham J et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 2006; 17: 291-302.
9. Fiandaca M, Forsayeth J, Dickinson P, Bankiewicz K. Image-guided convectionenhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008; 5: 123-127.
10. Salegio EA, Samaranch L, Kells AP, Forsayeth J, Bankiewicz K. Guided delivery of adeno-associated viral vectors into the primate brain. Adv Drug Deliv Rev 2012; 64: 598-604.
11. Hadaczek P, Yamashita Y, Mirek H, Tamas L, Bohn MC, Noble C et al. The 'perivascular pump' driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006; 14: 69-78.
12. Chamberlin NL, Du B, de Lacalle S, Saper CB. Recombinant adeno-associated virus vector: Use for transgene expression and anterograde tract tracing in the CNS. Brain Res 1998; 793: 169-175.
13. Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Therapy 2012; 20: 348-352.
14. Ciesielska A, Hadaczek P, Mittermeyer G, Zhou S, Wright JF, Bankiewicz KS et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 2013; 21: 158-166.
15. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
16. Walker FO. Huntington's disease. Lancet 2007; 369: 218-228.
17. Ross CA, Tabrizi SJ. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
18. Vagner T, Young D, Mouravlev A. Nucleic acid-based therapy approaches for Huntington's disease. Neurol Res Int 2012; 2012: 358370.
19. Kemp JM, Powell TP. The cortico-striate projection in the monkey. Brain 1970; 93: 525-546.
20. Selemon LD, Goldman-Rakic PS. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J Neurosci 1985; 5: 776-794.
21. Matsushita T, Elliger S, Elliiger C, Podsakoff G, Villarreal L, Kurtzman G et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Therapy 1998; 5: 938-945.
22. Wright J, Qu G, Tang C, Sommer J. Recombinant adeno-associated virus: Formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Dev 2003; 6: 174-178.
23. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005; 103: 923-929.
24. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011; 19: 1048-1057.